Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Gross Property, Plant and Equipment: €224.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
72 GF Score
Price €6.65
GF Value €3.71
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Gross Property, Plant and Equipment?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 -0.75% 72 Gross Property, Plant and Equipment is €224.2 Mil as of Jun. 2026. GuruFocus rates FRA:I54 with a GF Score™ of 72/100 and a GF Value™ of €3.71 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly gross PPE increased from Jun. 2025 (€163.4 Mil) to Dec. 2025 (€258.3 Mil) but then declined from Dec. 2025 (€258.3 Mil) to Jun. 2026 (€224.2 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual gross PPE increased from Dec. 2023 (€252.4 Mil) to Dec. 2024 (€262.3 Mil) but then declined from Dec. 2024 (€262.3 Mil) to Dec. 2025 (€258.3 Mil).


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Biocytogen Pharmaceuticals (Beijing) Co Gross Property, Plant and Equipment Related Terms


Biocytogen Pharmaceuticals (Beijing) Co Gross Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Gross Property, Plant and Equipment Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Property, Plant and Equipment
Get a 7-Day Free Trial 224.50 266.20 252.39 262.28 258.30

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.62 262.28 163.41 258.30 224.21
FRA:I54
72GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Gross Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Gross Property, Plant and Equipment of €224.2 Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Gross Property, Plant and Equipment of €224.2 Mil as of Jun. 2026. The total gross property, plant and equipment assets recorded on a company's balance sheet. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors.
Is Biocytogen Pharmaceuticals (Beijing) Co's Gross Property, Plant and Equipment too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Gross Property, Plant and Equipment is €224.2 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Gross Property, Plant and Equipment compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Gross Property, Plant and Equipment of €224.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Property, Plant and Equipment for a Biotechnology company?
A good Gross Property, Plant and Equipment depends on the Biotechnology industry context. However, Gross Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Property, Plant and Equipment mean?
A high Gross Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total gross property, plant and equipment assets recorded on a company's balance sheet. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Gross Property, Plant and Equipment is €224.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.71, compared to a current price of €6.65 — trading 79.2% above its estimated fair value. The current Gross Property, Plant and Equipment is €224.2 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Property, Plant and Equipment calculated?
Gross Property, Plant and Equipment is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Gross Property, Plant and Equipment is €224.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €6.65 is trading 79.2% above its estimated GF Value™ of €3.71. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for FRA:I54:

  • Gross Property, Plant and Equipment: €224.2 Mil
  • GF Value™: €3.71 vs. price of €6.65 (79.2% above fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
72GF Score

Get the complete analysis for FRA:I54

Gross Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.65
Price
€3.71
GF Value